Regulation of cytochrome b 5 Expression by miR-223 in human liver: Effects on cytochrome P450 activities

Pharmaceutical Research

Volumn 31, Issue 3, 2014, Pages 780-794

  Takahashi, Kei ^a   Oda, Yuki ^a   Toyoda, Yasuyuki ^a   Fukami, Tatsuki ^a   Yokoi, Tsuyoshi ^a,b   Nakajima, Miki ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

drug metabolizing enzymes; interindividual variability; post transcriptional regulation

Indexed keywords

CYTOCHROME B5; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; MESSENGER RNA; MICRORNA 223; TESTOSTERONE; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; MICRORNA; MIRN223 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ADENOVIRUS; ARTICLE; CELL FREE SYSTEM; CELL STRAIN HEPG2; CONTROLLED STUDY; DNA SEQUENCE; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROXYLATION; LIVER; LIVER MICROSOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; CELL LINE; GENE EXPRESSION REGULATION; GENETICS; HEPG2 CELL LINE; METABOLISM; NUCLEOTIDE SEQUENCE; OXIDATION REDUCTION REACTION;

3' UNTRANSLATED REGIONS; BASE SEQUENCE; CELL LINE; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; CYTOCHROMES B5; GENE EXPRESSION REGULATION; HEP G2 CELLS; HUMANS; HYDROXYLATION; LIVER; MICRORNAS; OXIDATION-REDUCTION; RNA, MESSENGER; TESTOSTERONE;

EID: 84895441420     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1200-7     Document Type: Article

References (40)

1. 5. Pharmacol Ther. 2003;97:139-52.
2. 5: novel roles in steroidogenesis. Mol Cell Endocrinol. 2013;371:87-99.
3. 5 reductase of erythrocytes and liver microsomes. Biochim Biophys Acta. 1976;423:293-302.
4. 5 interactions and the kinetic mechanism of metmyoglobin reductase. J Biol Chem. 1985;260:15699-707.
5. 5 in cytochrome P450 reactions. J Biochem Mol Toxicol. 2002;16:311-6.
6. 5. N Engl J Med. 1986;314:757-61.
7. 5 profoundly affects hepatic and extrahepatic drug metabolism. Mol Pharmacol. 2010;78:269-78.
8. 5. J Biol Chem. 2008;283:31385-93.
9. Nelson DR, Zeldin DC, Hoffman SM, Maltais LJ, Wain HM, Nebert DW. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics. 2004;14:1-18.
10. Guengerich FP. Rate-limiting steps in cytochrome P450 catalysis. Biol Chem. 2002;383:1553-64.
11. 5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. Protein Expr Purif. 2002;24:329-37.
12. 5 with cytochromes P4503A4 and P45017A: relevance of heme transfer reactions. Biochemistry. 2001;40:5018-31.
13. 5 gene transcription by Sp3, GATA-6, and steroidogenic factor 1 in human adrenal NCI-H295A cells. Mol Endocrinol. 2005;19:2020-34.
14. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281-97.
15. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 2010;9:775-89.
16. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2001;19:92-105.
17. Ambros V. The functions of animal microRNAs. Nature. 2004;431:350-5.
18. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004;101:2999-3004.
19. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435:834-8.
20. Nakajima M, Yokoi T. MicroRNAs from biology to future pharmacotherapy: regulation of cytochrome P450s and nuclear receptors. Pharmacol Ther. 2011;131:330-7.
21. Tsuchiya Y, Nakajima M, Takagi S, Taniya T, Yokoi T. MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res. 2006;66:9090-8.
22. Mohri T, Nakajima M, Fukami T, Takamiya M, Aoki Y, Yokoi T. Human CYP2E1 is regulated by miR-378. Biochem Pharmacol. 2010;79:1045-52.
23. Komagata S, Nakajima M, Takagi S, Mohri T, Taniya T, Yokoi T. Human CYP24 catalyzing the inactivation of calcitriol is post-transcriptionally regulated by miR-125b. Mol Pharmacol. 2009;76:702-9.
24. Tabata T, Katoh M, Tokudome S, Hosokawa M, Chiba K, Nakajima M, et al. Bioactivation of capecitabine in human liver: involvement of the cytosolic enzyme on 5′-deoxy-5-fluorocytidine formation. Drug Metab Dispos. 2004;32:762-7.
25. Omura T, Sato R. The carbon monooxide-binding pigment of liver microsomes. I. evidence for its hemoprotein nature. J Biol Chem. 1964;239:2370-8.
26. Yoshitomi S, Ikemoto K, Takahashi J, Miki H, Namba M, Asahi S. Establishment of the transformants expressing human cytochrome P450 subtypes in HepG2, and their applications on drug metabolism and toxicology. Toxicol in Vitro. 2001;15:245-56.
27. Tsuchiya Y, Nakajima M, Kyo S, Kanaya T, Inoue M, Yokoi T. Human CYP1B1 is regulated by estradiol via estrogen receptor. Cancer Res. 2004;64:3119-25.
28. Hosomi H, Akai S, Minami K, Yoshikawa Y, Fukami T, Nakajima M, et al. An in vitro drug-induced hepatotoxicity screening system using CYP3A4-expressing and γ-glutamylcysteine synthetase knockdown cells. Toxicol in Vitro. 2010;24:1032-8.
29. Oda S, Nakajima M, Toyoda Y, Fukami T, Yokoi T. Progesterone receptor membrane component 1 modulates human cytochrome P450 activities in an isoform-dependent manner. Drug Metab Dispos. 2011;39:2057-65.
30. Wong QW, Lung RW, Law PT, Lai PB, Chan KY, To KF, et al. MicroRNA-223 is commonly expressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology. 2008;135:257-69.
31. 5 interactions. Arch Biochem Biophys. 1997;342:329-37.
32. Alexiou P, Maragkakis M, Papadopoulos GL, Reczko M, Hatzigeorgiou AG. Lost in translation: an assessment and perspective for computational microRNA target identification. Bioinformatics. 2009;25:3049-55.
33. 5 in hepatic microsomal mixed-function oxidation reactions. Arch Biochem Biophys. 1971;143:66-79.
34. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science. 2004;303:83-6.
35. Stamatopoulos B, Meuleman N, Haibe-Kains B, Saussoy P, Van Den Neste E, Michaux L, et al. microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Blood. 2009;113:5237-45.
36. Liu TY, Chen SU, Kuo SH, Cheng AL, Lin CW. E2A-positive gastric MALT lymphoma has weaker plasmacytoid infiltrates and stronger expression of the memory B-cell-associated miR-223: possible correlation with stage and treatment response. Mod Pathol. 2010;23:1507-17.
37. Laios A, O'Toole S, Flavin R, Martin C, Kelly L, Ring M, et al. Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer. 2008;7:35.
38. Fazi F, Rosa A, Fatica A, Gelmetti V, De Marchis ML, Nervi C, et al. A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPα regulates human granulopoiesis. Cell. 2005;123:819-31.
39. Fukao T, Fukuda Y, Kiga K, Sharif J, Hino K, Enomoto Y, et al. An evolutionarily conserved mechanism for microRNA-223 expression revealed by microRNA gene profiling. Cell. 2007;129:617-31.
40. Dai R, Phillips RA, Zhang Y, Khan D, Crasta O, Ahmed SA. Suppression of LPS-induced Interferon-γ and nitric oxide in splenic lymphocytes by select estrogen-regulated microRNAs: a novel mechanism of immune modulation. Blood. 2008;112:4591-7.